A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells

Translation of the CRISPR–Cas9 system to human therapeutics holds high promise. However, specificity remains a concern especially when modifying stem cell populations. We show that existing rationally engineered Cas9 high-fidelity variants have reduced on-target activity when using the therapeutically relevant ribonucleoprotein (RNP) delivery method. Therefore, we devised an unbiased bacterial screen to isolate variants that retain activity in the RNP format. Introduction of a single point mutation, p.R691A, in Cas9 (high-fidelity (HiFi) Cas9) retained the high on-target activity of Cas9 while reducing off-target editing. HiFi Cas9 induces robust AAV6-mediated gene targeting at five therapeutically relevant loci (HBB, IL2RG, CCR5, HEXB, and TRAC) in human CD34+ hematopoietic stem and progenitor cells (HSPCs) as well as primary T cells. We also show that HiFi Cas9 mediates high-level correction of the sickle cell disease (SCD)-causing p.E6V mutation in HSPCs derived from patients with SCD. We anticipate that HiFi Cas9 will have wide utility for both basic science and therapeutic genome-editing applications.A bacterial screen yields a Cas9 variant that retains high on-target activity when delivered in the RNP format. As proof of principle, this Cas9 variant enables high-level correction of the sickle cell disease mutation in patient-derived HSPCs.

[1]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[2]  Jennifer A. Doudna,et al.  Conformational control of DNA target cleavage by CRISPR–Cas9 , 2015, Nature.

[3]  Martin J. Aryee,et al.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.

[4]  Luigi Naldini,et al.  Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 , 2017, Science Translational Medicine.

[5]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[6]  Barry L. Wanner,et al.  Use of New Methods for Construction of Tightly Regulated Arabinose and Rhamnose Promoter Fusions in Studies of theEscherichia coli Phosphate Regulon , 1998, Journal of bacteriology.

[7]  A. Baiker,et al.  Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. , 2012, Human gene therapy methods.

[8]  Suresh Ramakrishna,et al.  Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA , 2014, Genome research.

[9]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[10]  Philippe Horvath,et al.  crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus , 2013, RNA biology.

[11]  R. Bak,et al.  CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. , 2017, Cell reports.

[12]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[13]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[14]  Aaron J. Martin,et al.  Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Leslie S. Edwards,et al.  Mapping the genomic landscape of CRISPR–Cas9 cleavage , 2017, Nature Methods.

[16]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[17]  Aaron R Cooper,et al.  CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[19]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.

[20]  A. Look,et al.  Bone-marrow transplantation in a patient with sickle-cell anemia. , 1984, The New England journal of medicine.

[21]  P. Gregory,et al.  Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery , 2015, Nucleic acids research.

[22]  Irene Georgakoudi,et al.  Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles , 2016, Proceedings of the National Academy of Sciences.

[23]  Jennifer A. Doudna,et al.  Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.

[24]  Nevan J Krogan,et al.  A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. , 2016, Cell reports.

[25]  Aaron R. Quinlan,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[26]  Namritha Ravinder,et al.  Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. , 2015, Journal of biotechnology.

[27]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[28]  Channabasavaiah B. Gurumurthy,et al.  Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes , 2017, Methods.

[29]  R. Gatti,et al.  Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.

[30]  Lei Zhang,et al.  Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.

[31]  Margaret A Goodell,et al.  Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. , 2016, Cell reports.

[32]  M. Porteus.  Towards a new era in medicine: therapeutic genome editing , 2015, Genome Biology.

[33]  J. Kent,et al.  Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR , 2016, Genome Biology.

[34]  Castle Raley,et al.  Targeted Gene Addition to a Safe Harbor locus in human CD34+ Hematopoietic Stem Cells for Correction of X-linked Chronic Granulomatous Disease , 2016, Nature Biotechnology.

[35]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[36]  Pachai Natarajan,et al.  CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease , 2017, Science Translational Medicine.

[37]  S. Haas,et al.  Technical considerations for the use of CRISPR/Cas9 in hematology research. , 2017, Experimental hematology.

[38]  J. Nicklas,et al.  Use of inverse PCR to amplify and sequence breakpoints of HPRT deletion and translocation mutations , 2002, Environmental and molecular mutagenesis.

[39]  A. Baiker,et al.  Universal Real-Time PCR for the Detection and Quantification of Adeno-Associated Virus Serotype 2-Derived Inverted Terminal Repeat Sequences , 2011 .

[40]  L. Chicaybam,et al.  An Efficient Low Cost Method for Gene Transfer to T Lymphocytes , 2013, PloS one.

[41]  Peng Qiu,et al.  COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites , 2014, Molecular therapy. Nucleic acids.

[42]  R. Hardison,et al.  A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition , 2016, Nature Medicine.

[43]  Dana Carroll,et al.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.

[44]  Steven Salzberg,et al.  BIOINFORMATICS ORIGINAL PAPER , 2004 .

[45]  N. Lennon,et al.  Characterizing and measuring bias in sequence data , 2013, Genome Biology.

[46]  M. Porteus,et al.  The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation , 2017, Current opinion in hematology.

[47]  N. Taylor,et al.  Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo. , 2013, Blood.

[48]  J. Doudna,et al.  A conformational checkpoint between DNA binding and cleavage by CRISPR-Cas9 , 2017, Science Advances.

[49]  E. Kass,et al.  Collaboration and competition between DNA double‐strand break repair pathways , 2010, FEBS letters.

[50]  David R. Liu,et al.  Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery , 2017, Nature Communications.

[51]  Zhilei Chen,et al.  A highly sensitive selection method for directed evolution of homing endonucleases , 2005, Nucleic acids research.

[52]  Michael L Kaufman,et al.  β-globin gene transfer to human bone marrow for sickle cell disease. , 2013, The Journal of clinical investigation.

[53]  M. Behlke,et al.  RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers , 2011, BMC biotechnology.

[54]  Jennifer A. Doudna,et al.  Generation of knock-in primary human T cells using Cas9 ribonucleoproteins , 2015, Proceedings of the National Academy of Sciences.

[55]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[56]  Andreas Reinisch,et al.  Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6 , 2017, eLife.

[57]  D. Russell,et al.  AAV-mediated gene targeting methods for human cells , 2011, Nature Protocols.

[58]  A. Scharenberg,et al.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template , 2015, Science Translational Medicine.

[59]  Alessandro Romanel,et al.  A highly specific SpCas9 variant is identified by in vivo screening in yeast , 2018, Nature Biotechnology.

[60]  George M. Church,et al.  Genome editing assessment using CRISPR Genome Analyzer (CRISPR-GA) , 2014, Bioinform..

[61]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[62]  John Hale,et al.  Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. , 2016, Blood.

[63]  H. Swerdlow,et al.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.

[64]  Jennifer A. Doudna,et al.  A conformational checkpoint between DNA binding and cleavage by CRISPR-Cas9 , 2017 .

[65]  Christof von Kalle,et al.  Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  P. Gregory,et al.  Homology-driven genome editing in hematopoietic stem and progenitor cells using zinc finger nuclease mRNA and AAV6 donors , 2015, Nature Biotechnology.

[67]  Daniel G. Anderson,et al.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.

[68]  G. Lucarelli,et al.  Allogeneic marrow transplantation for thalassemia. , 1984, Experimental hematology.

[69]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[70]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[71]  M. Behlke,et al.  Non-nucleotide Modification of Anti-miRNA Oligonucleotides. , 2017, Methods in molecular biology.

[72]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[73]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[74]  Gang Bao,et al.  The Neisseria meningitidis CRISPR-Cas9 System Enables Specific Genome Editing in Mammalian Cells , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.